RS99304A - Methods of treating hepatitis - Google Patents

Methods of treating hepatitis

Info

Publication number
RS99304A
RS99304A YUP-993/04A YUP99304A RS99304A RS 99304 A RS99304 A RS 99304A YU P99304 A YUP99304 A YU P99304A RS 99304 A RS99304 A RS 99304A
Authority
RS
Serbia
Prior art keywords
methods
treating hepatitis
patient
hepatitis
treating
Prior art date
Application number
YUP-993/04A
Other languages
English (en)
Inventor
Leo Otterbein
Augustine Choi
Brian Zuckerbraun
Original Assignee
Yale University,
University Of Pittsburgh Of The Commonwealth System Of Higher Education,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University,, University Of Pittsburgh Of The Commonwealth System Of Higher Education, filed Critical Yale University,
Publication of RS99304A publication Critical patent/RS99304A/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • External Artificial Organs (AREA)

Abstract

Predmetni pronalazak se odnosi na postupak za lečenje hepatitisa kod pacijenta, koji obuhvata primenu na pacijentu farmaceutskog preparata koji sadrži ugljen monoksid.
YUP-993/04A 2002-05-17 2003-05-16 Methods of treating hepatitis RS99304A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38152702P 2002-05-17 2002-05-17
PCT/US2003/015263 WO2003096977A2 (en) 2002-05-17 2003-05-16 Methods of treating hepatitis

Publications (1)

Publication Number Publication Date
RS99304A true RS99304A (en) 2007-04-10

Family

ID=29550139

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-993/04A RS99304A (en) 2002-05-17 2003-05-16 Methods of treating hepatitis

Country Status (16)

Country Link
US (4) US20040052866A1 (sr)
EP (1) EP1505990B1 (sr)
JP (1) JP4549847B2 (sr)
CN (1) CN1668314B (sr)
AT (1) ATE521357T1 (sr)
CA (1) CA2485465A1 (sr)
DK (1) DK1505990T3 (sr)
EA (1) EA200401525A1 (sr)
ES (1) ES2372273T3 (sr)
HR (1) HRP20041071A2 (sr)
MX (1) MXPA04011426A (sr)
NO (1) NO20045056L (sr)
PL (1) PL205066B1 (sr)
RS (1) RS99304A (sr)
UA (1) UA83465C2 (sr)
WO (1) WO2003096977A2 (sr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678390B2 (en) 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
DE60229848D1 (de) * 2001-06-21 2008-12-24 Beth Israel Hospital - und organtransplantationen und unterdrückt apoptose
US20080026984A1 (en) * 2002-02-04 2008-01-31 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
NZ534912A (en) * 2002-02-04 2007-08-31 Alfama Investigacao E Desenvol supramolecule aggregate comprising CO containing organometallic or transition metal complex and anti-inflammatory agent or biphosphonate phosphonate derivative
US7968605B2 (en) * 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
JP2005522521A (ja) 2002-04-15 2005-07-28 ベス イスラエル デアコネス メディカル センター ヘムオキシゲナーゼ−１およびヘム分解産物の使用法
US7981448B2 (en) * 2002-04-15 2011-07-19 University Of Pittsburgh Methods of treating necrotizing enterocolitis
PL373002A1 (en) * 2002-04-15 2005-08-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating ileus
US20040052866A1 (en) 2002-05-17 2004-03-18 Otterbein Leo E. Methods of treating hepatitis
JP2005532351A (ja) * 2002-06-05 2005-10-27 イエール ユニバーシティ 血管形成、腫瘍増殖、および転移を治療する方法
CA2490392A1 (en) * 2002-06-21 2003-12-31 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
AU2003283982A1 (en) * 2002-11-07 2004-06-03 University Of Pittsburgh Of The Commonwealth System Of High Education Treatment for hemorrhagic shock
GB2395432B (en) * 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
US20040218547A1 (en) 2003-04-30 2004-11-04 Rhodey William George Process modification to maximize benzene production
US20070207993A1 (en) * 2005-12-20 2007-09-06 Alfama - Investigacao E Desenvolvimetno De Productos Farmaceuticos Lda Molybdenum carbonyl complexes for treating rheumatoid arthritis and other inflammatory diseases
WO2007073226A1 (en) * 2005-12-20 2007-06-28 Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda Method for treating a mammal by administration of a compound having the ability to release co
JPWO2007073006A1 (ja) * 2005-12-22 2009-06-04 学校法人慶應義塾 細胞保護性を有するアミノ酸の増加誘導剤及び増加方法
WO2007073005A1 (ja) * 2005-12-22 2007-06-28 Keio University メチル基転移反応調節物質
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
US20100086519A1 (en) * 2008-10-03 2010-04-08 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center Treatment of Hepatitis C Infection With Metalloporphyrins
LT3210644T (lt) 2009-05-27 2019-02-11 Ino Therapeutics Llc Įrenginiai, skirti sugraduoto vožtuvo ir hermetiško kanistro įrenginio sukabinimui be sandariklio
JP2011010865A (ja) 2009-06-30 2011-01-20 Ikaria Holdings Inc 肺高血圧の臨床的または超音波心臓検査上の証拠を伴う低酸素性呼吸器不全に罹った満期産およびほぼ満期産の新生児を治療する方法
US20120177601A1 (en) * 2009-07-02 2012-07-12 The Usa As Represented By The Secretary Of The Department Of Veterans Affairs Treatment of hepatitis c virus infections
WO2012145520A2 (en) 2011-04-19 2012-10-26 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
ES2628634T3 (es) 2011-07-21 2017-08-03 Alfama, Inc. Moléculas liberadoras de monóxido de carbono-rutenio y usos de las mismas
CA2844660A1 (en) 2011-08-09 2013-02-14 Leo E. Otterbein Methods of treating dna damage
JP6457749B2 (ja) * 2013-12-27 2019-01-23 ハウスウェルネスフーズ株式会社 Ｖｃａｍ−１発現抑制剤
TW201618795A (zh) 2014-04-15 2016-06-01 波泰里斯股份有限公司 用以改良器官功能及延長器官移植物壽命之系統及方法
CN108057032B (zh) * 2018-01-30 2020-06-05 中国人民解放军第二军医大学第二附属医院 阿尔维林在制备预防或治疗门脉高压症的药物中的应用
EP3524290A1 (en) * 2018-02-09 2019-08-14 Julius-Maximilians-Universitaet Wuerzburg Method and system for monitoring carbon monoxide (co) administration to ex-vivo fluids

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4053590A (en) * 1975-02-27 1977-10-11 Alza Corporation Compositions of matter comprising macromolecular hemoglobin
US4264739A (en) * 1979-01-05 1981-04-28 Merck & Co., Inc. Sparger for cell culture system
JPS5679957A (en) 1979-12-05 1981-06-30 Sogo Seibutsu Igaku Kenkyusho:Kk Erucinia enterocolitica polysaccharide sensitizing blood cell and method of detecting erucinia enterocolitica polysaccharide antibody using this
US5240912A (en) * 1983-05-09 1993-08-31 Todaro George J Transforming growth factor (TGF) peptides
US5084380A (en) * 1985-01-29 1992-01-28 Applied Biotechnology Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
US5449665A (en) * 1985-09-24 1995-09-12 Item Development Aktiebolag Continuous intravenous infusion of adenosine to human patients undergoing percutaneous transluminal angioplasty
DE3739650C1 (de) * 1987-11-23 1989-05-24 Immuno Ag Fermenter zum Zuechten von Zellkulturen
US5180366A (en) * 1990-10-10 1993-01-19 Woods W T Apparatus and method for angioplasty and for preventing re-stenosis
US5792325A (en) * 1990-11-15 1998-08-11 Richardson, Jr.; William H. Electric arc material processing system
US5293875A (en) * 1992-06-16 1994-03-15 Natus Medical Incorporated In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods
EP0693924B2 (en) * 1993-02-22 2008-04-09 Abraxis BioScience, Inc. Methods for (in vivo) delivery of biologics and compositions useful therefor
WO1994022482A1 (en) 1993-03-26 1994-10-13 Biorelease Technologies, Inc. Compositions including heme-containing proteins and methods relating thereto
US5763431A (en) * 1993-08-20 1998-06-09 Jackson; Meyer B. Method for regulating neuropeptide hormone secretion
DE4421433C1 (de) 1994-06-18 1995-06-08 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung
US5476764A (en) * 1994-09-16 1995-12-19 The Regents Of The University Of California Method using CO for extending the useful shelf-life of refrigerated red blood cells
US6066333A (en) * 1994-09-22 2000-05-23 William Harvey Research Limited Pharmaceutical control of inflammation
US5664563A (en) * 1994-12-09 1997-09-09 Cardiopulmonary Corporation Pneumatic system
US5914316A (en) * 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
FR2735382B1 (fr) 1995-06-15 1997-07-25 Air Liquide Installation de production de monoxyde de carbone incorporant une unite de separation cryogenique
EP0835115B1 (en) * 1995-06-30 2004-05-06 ZymoGenetics, Inc. 4-(2-(n-2-carboxamidoindole)aminoethyl)-benzenesulfonamides or sulfonylureas as pdgf antagonists
US5702325A (en) 1996-01-30 1997-12-30 Icon Health & Fitness, Inc. Cabinet treadmill with handle
AU4719296A (en) * 1996-02-27 1997-09-16 Intensive Care Innovations Ltd. Ventilatory system with additional gas administrator
ATE331505T1 (de) * 1996-04-05 2006-07-15 Gen Hospital Corp Behandlung einer hämoglobinstörung
US6069132A (en) * 1996-08-14 2000-05-30 Revanker; Ganapathi R. Phosphazole compounds
CN1191836C (zh) 1996-08-27 2005-03-09 梅塞尔集团有限公司 氢气作为药物活性成分在制备药物产品中的用途
US8128963B2 (en) * 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US6316403B1 (en) * 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US6315995B1 (en) 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
ES2285740T3 (es) * 1996-09-27 2007-11-16 The Trustees Of Columbia University In The City Of New York Tratamiento de un trastorno isquemico y mejora de las consecuencias de un accidente cerebrovascular.
US5876604A (en) * 1996-10-24 1999-03-02 Compact Membrane Systems, Inc Method of gasifying or degasifying a liquid
ES2243052T3 (es) 1998-03-16 2005-11-16 Celgene Corporation Derivados de la 2- (2,6-dioxopiperidin-3-il) isoindolina, su preparacion y su empleo como inhibidores de las citocinas inflamatorias.
US6203991B1 (en) * 1998-08-21 2001-03-20 The Regents Of The University Of Michigan Inhibition of smooth muscle cell migration by heme oxygenase I
US7678390B2 (en) * 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
US20050250688A1 (en) * 1999-04-01 2005-11-10 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US7632803B2 (en) * 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
FR2812197B1 (fr) 2000-07-27 2003-01-03 Air Liquide Sante Int Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches
FR2812545B1 (fr) * 2000-08-03 2003-03-28 Air Liquide Sante Int Aerosol medicamenteux inhalable dans le traitement ou la prevention de la douceur
FR2816212A1 (fr) 2000-11-03 2002-05-10 Air Liquide Sante Int Utilisation de monoxyde de carbone (co) dans le traitement des inflammations du systeme cardiovasculaire
WO2002080859A2 (en) * 2001-03-20 2002-10-17 Glaxo Group Limited Inhalation drug combinations
JP2004526739A (ja) 2001-03-30 2004-09-02 サングスタット メディカル コーポレイション 血管の、炎症性の及び免疫の障害の治療のための、一酸化炭素生成性化合物
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
EP1395241B9 (en) * 2001-05-25 2005-06-15 Medtronic, Inc. Implantable medical device with controllable gaseous agent release system
DE60229848D1 (de) * 2001-06-21 2008-12-24 Beth Israel Hospital - und organtransplantationen und unterdrückt apoptose
US7174178B2 (en) 2001-07-19 2007-02-06 Intel Corporation Deriving a more accurate estimate from prediction data in closed loop transmit diversity modes
NZ534912A (en) * 2002-02-04 2007-08-31 Alfama Investigacao E Desenvol supramolecule aggregate comprising CO containing organometallic or transition metal complex and anti-inflammatory agent or biphosphonate phosphonate derivative
WO2003072024A2 (en) * 2002-02-13 2003-09-04 Beth Israel Deaconess Medical Center, Inc. Methods of treating vascular disease
JP2005522521A (ja) * 2002-04-15 2005-07-28 ベス イスラエル デアコネス メディカル センター ヘムオキシゲナーゼ−１およびヘム分解産物の使用法
PL373002A1 (en) * 2002-04-15 2005-08-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating ileus
US7981448B2 (en) * 2002-04-15 2011-07-19 University Of Pittsburgh Methods of treating necrotizing enterocolitis
CA2484770A1 (en) * 2002-05-09 2003-11-20 Yale University Carbon monoxide as a biomarker and therapeutic agent
US20040052866A1 (en) 2002-05-17 2004-03-18 Otterbein Leo E. Methods of treating hepatitis
JP2005532351A (ja) 2002-06-05 2005-10-27 イエール ユニバーシティ 血管形成、腫瘍増殖、および転移を治療する方法
CA2490392A1 (en) * 2002-06-21 2003-12-31 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
DE10230165A1 (de) 2002-07-04 2004-01-15 Ino Therapeutics Gmbh Verfahren und Vorrichtung zur Administration von Kohlenmonoxid
AU2003283982A1 (en) 2002-11-07 2004-06-03 University Of Pittsburgh Of The Commonwealth System Of High Education Treatment for hemorrhagic shock
WO2005077005A2 (en) 2004-02-04 2005-08-25 The General Hospital Corporation Enhancing the effectiveness of an inhaled therapeutic gas

Also Published As

Publication number Publication date
CA2485465A1 (en) 2003-11-27
CN1668314A (zh) 2005-09-14
US9522163B2 (en) 2016-12-20
ATE521357T1 (de) 2011-09-15
NO20045056L (no) 2005-02-16
JP2005533021A (ja) 2005-11-04
EP1505990A2 (en) 2005-02-16
US20140141103A1 (en) 2014-05-22
HRP20041071A2 (en) 2005-06-30
EP1505990A4 (en) 2008-02-20
US20040052866A1 (en) 2004-03-18
MXPA04011426A (es) 2005-10-19
DK1505990T3 (da) 2011-11-21
EP1505990B1 (en) 2011-08-24
US20120276220A1 (en) 2012-11-01
CN1668314B (zh) 2011-01-12
UA83465C2 (uk) 2008-07-25
JP4549847B2 (ja) 2010-09-22
WO2003096977A3 (en) 2004-03-11
US20130202720A1 (en) 2013-08-08
AU2003234585A1 (en) 2003-12-02
EA200401525A1 (ru) 2006-06-30
PL374177A1 (en) 2005-10-03
ES2372273T3 (es) 2012-01-17
WO2003096977A2 (en) 2003-11-27
PL205066B1 (pl) 2010-03-31

Similar Documents

Publication Publication Date Title
HRP20041071A2 (en) Methods of treating hepatitis
RS91004A (en) Methods of treating ileus
RS91104A (en) Methods of treating necrotizing enterocolitis
PL373229A1 (en) Method and apparatus for the administration of co
RS105304A (en) Methods of treating angiogenesis,tumor growth,and metastasis
RS20050344A (en) Treatment for hemorrhagic shock
EP1670450B8 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
MX349188B (es) Sns - 595 y metodos para utilizar el mismo.
UA92894C2 (ru) Способ приготовления и применения композиции адсорбента фосфата, адсорбент фосфата, композиция адсорбента фосфата
HK1086186A1 (en) Use of spongosine (2-methoxyadenosein) for preparing pharmaceutical for the treatment of pain
MXPA05009786A (es) Composicion para administracion de hierro para el tratamiento del sindrome de piernas inquietas.
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
PL1694354T3 (pl) Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
TW200509984A (en) Injectable dosage form of flupirtine
MXPA05005915A (es) Soluciones de albumina humana terapeutica con baja actividad del activador de precalicreina (pka) y procedimiento de obtencion de las mismas.
DE60335535D1 (de) Zusammensetzung und verfahren zur abtötung von tumoren
PL375354A1 (en) Use of treosulfan and derivatives thereof for treating multiple sclerosis
UA29106A (uk) Спосіб лікування вібраційної хвороби